Electronic Thesis/Dissertation


Provision of Antigen-Specific CD4+ T cells Prevents the Tolerization of CD8+ Tumor-Specific T cells in a Mouse Model of Prostate Cancer Open Access

Downloadable Content

Download PDF

T cell tolerance to tumor antigens is a considerable challenge to cancer immunotherapy. To study T cell tolerance to tumor antigens, our laboratory utilizes the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model in combination with adoptive transfer of TcR transgenic T cells with specificity for a TRAMP tumor antigen. We previously reported that adoptive transfer of tumor-specific CD8+ (TcR-I) T cells into TRAMP mice resulted in their rapid tolerization. The objective of the current study was to test the ability CD4+ (TcR-II) T cells to enhance anti-tumor immunity by preventing TcR-I cell tolerance. CD4+ T cells play a central role in orchestrating the initial priming and the maintenance of immunity and have been shown to contribute to the development of effective anti-tumor immune responses. Naïve TcR-II adoptively transferred into TRAMP mice alone became activated in LN and trafficked to the prostate. Within the prostate, TcR-II cells initially functioned as T helper-1 (TH1) cells, as measured by their ability to secrete IL-2 or IFN-γ in response to their cognate tumor antigen, but became tolerant by 10 days after transfer. We next tested whether the transient activation of TcR-II T cells was sufficient to prevent the toleriazation of TcR-I T cells. Co-transfer of naïve TcR-II T cells with TcR-I T cells initially enhanced the expansion, activation, and function of TcR-I T cells. While a single co-transfer was insufficient to maintain TcR-I-mediated anti-tumor responsiveness, sustained provision of TcR-II help prevented tolerization of TcR-I cells and ultimately reduced tumor progression. These data demonstrate that tumor-specific CD4+ T cells are essential for the expansion, differentiation, and maintenance of anti-tumor CTL activity and can prevent the immunosuppressive tolerization of tumor-specific CTLs. In addition, delivery of tumor-specific CD4+ helper T cells also prevented the conversion of TcR-I cells into suppressor cells. Within TRAMP prostates, TcR-I cells acquired the capability to suppress the proliferation of naïve CD4+ and CD8+ T cells and exhibited a surface phenotype similar to regulatory T cells. This suppression was mediated at least inpart by secreted factors including TGF-&beta.; Taken together, these data demonstrate that the powerful immunosuppressive environment of the developing TRAMP tumor can exert its effect on T cells. By studying the ability of CD4+ T cells to enhance anti-tumor CTL activity, we hope to elucidate novel approaches to stimulate a more potent anti-tumor immune response. Maintaining T cell responses that favor anti-tumor immunity over the induction of tolerance or suppressor activity in the tumor microenvironment may have critical implications on the efficacy of cancer immunotherapies.

Author Language Keyword Date created Type of Work Rights statement GW Unit Degree Advisor Committee Member(s) Persistent URL